Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;173(3):641-50.
doi: 10.1111/bjd.14016. Epub 2015 Aug 25.

Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo

K C Webb  1 , R Tung  1 , L S Winterfield  1 , A B Gottlieb  2 , J M Eby  3 , S W Henning  3 , I C Le Poole  4
Affiliations
Review

Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo

K C Webb et al. Br J Dermatol. 2015 Sep.

Abstract

Tumour necrosis factor (TNF)-α, a proinflammatory cytokine central to many autoimmune diseases, has been implicated in the depigmentation process in vitiligo. We review its role in vitiligo by exploring its pro- and anti-inflammatory properties and examine the effects of blocking its actions with TNF-α antagonist therapeutics in reports available in the literature. We found that TNF-α inhibition halts disease progression in patients with progressive vitiligo but that, paradoxically, treatment can be associated with de novo vitiligo development in some patients when used for other autoimmune conditions, particularly when using adalimumab and infliximab. These studies reinforce the importance of stating appropriate outcomes measures, as most pilot trials propose to measure repigmentation, whereas halting depigmentation is commonly overlooked as a measure of success. We conclude that TNF-α inhibition has proven useful for patients with progressive vitiligo, where TNF-α inhibition is able to quash cytotoxic T-cell-mediated melanocyte destruction. However, a lingering concern for initiating de novo disease will likely prevent more widespread application of TNF inhibitors to treat vitiligo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of tumour necrosis factor (TNF)‐α inhibition in patients with progressive vitiligo (left) and in patients without vitiligo (right). In patients with progressive vitiligo (left), successful halting of depigmentation is observed with the use of TNF‐α inhibitors. In the skin of patients with progressive vitiligo, there is a surplus of cytotoxic T lymphocytes (CTLs) and a relative deficiency of regulatory T cells (Tregs) to suppress cytotoxic effects. With the addition of TNF‐α inhibitors, there is preferential inhibition of the effects of TNF‐α on CD8+ T‐cell activation and proliferation, resulting in reduced melanocyte destruction. In patients without vitiligo, a surplus of CTLs in the skin is not observed, and Treg numbers are normal. Thus, inhibiting TNF‐α instead preferentially inhibits the ability of TNF‐α to promote the activation and proliferation of Tregs, resulting in removal of the skin's innate protection against depigmentation and de novo vitiligo development (right). On the left, in progressive vitiligo, TNF‐α induces CTL activation and proliferation (Box 1), and upregulates expression of melanocyte cell‐surface molecules that result ultimately in melanocyte destruction (Box 2). With TNF‐α inhibitor therapy, CTL activation and proliferation is inhibited (Box 3), resulting in melanocyte survival and halted depigmentation (Box 4). On the right, in patients without vitiligo, an increase in cutaneous self‐reactive CTLs is not observed. Instead, immunological homeostasis exists, with a normal amount of Tregs suppressing effects of any self‐reactive CD8+ T cells. TNF‐α induces activation and proliferation of Tregs in the skin (Box 1). When TNF‐α is inhibited, Treg activation and proliferation are inhibited (Box 2), and self‐reactive cutaneous CD8+ T cells can destroy cutaneous melanocytes (Box 3), resulting in de novo vitiligo development (Box 4). ICAM, intercellular adhesion molecule; TNFR, TNF receptor.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J Am Acad Dermatol 1991; 24:675–85. - PubMed
    1. Vassali P. The pathophysiology of tumour necrosis factor. Annu Rev Immunol 1992; 10:411–52. - PubMed
    1. Aggarwal BB. Signaling pathways of the TNF superfamily: a double‐edged sword. Nat Rev Immunol 2003; 3:745–56. - PubMed
    1. Spriggs DR, Deutsch S, Kufe DW. Genomic structure, induction, and production of TNF‐alpha. Immunol Ser 1992; 56:3–34. - PubMed
    1. Black RA, Rauch CT, Kozlosky CT et al A metalloproteinase disintegrin that releases tumour‐necrosis factor‐alpha from cells. Nature 1997; 385:729–33. - PubMed

Publication types

Substances